LSTA Lisata Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$1.47
· of 52w range
· above low
· to high
$0.9952w low
$5.0752w high
Market Cap (MRQ)
$13M
P/E (TTM)
-0.9
EPS (TTM)
$-1.64
Revenue (TTM)
$100.0K
your badges
52W Range
$1–$5
Analyst Rating
BUY
Price Target
$4
P/E
-0.9
ROE
-99.9%
Net Profit Margin
-14621.0%
Your badge strip is empty — pin a metric anywhere on this page.
LSTA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.47
Market Cap (MRQ)
$13M
P/E (TTM)
-0.9
EPS (TTM)
$-1.64
Revenue (TTM)
$100.0K
ROE (TTM)
-99.9%
52W Range
$1–$5
LSTA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Sept. 15, 2022 | 1-for-15 | Reverse |
| July 28, 2016 | 1-for-10 | Reverse |
| July 16, 2013 | 1-for-10 | Reverse |
| Aug. 9, 2007 | 1-for-10 | Reverse |
| Aug. 31, 2006 | 1-for-10 | Reverse |
About Lisata Therapeutics, Inc. - Common Stock Company overview from Wikipedia
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide (also known as iRGD and CEND-1), orphan drug status in pancreatic cancer, followed by a Fast track (FDA) status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees21
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$170.0K2016-12-31 → 2025-12-31
EPS$-1.912016-12-31 → 2025-12-31
Free Cash Flow·2016-12-31 → 2023-12-31
Net margin-14621.0%2016-12-31 → 2024-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | LSTA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -0.95Y avg ≈-1.0 | ≈-1.0 | · | · | |
| P/S (TTM) | 134.0 | · | · | · | |
| P/B (MRQ) | 1.65Y avg ≈0.5 | ≈0.5 | · | · | |
| Price / FCF (TTM) | -1.1 | · | · | · | |
| Price / Cash Flow (TTM) | -1.15Y avg ≈-1.1 | ≈-1.1 | · | · | |
| Price / Tangible Book (MRQ) | 1.75Y avg ≈2.2 | ≈2.2 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | LSTA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -16428.0% | · | · | · | |
| Pretax Margin (TTM) | -15008.0% | · | · | · | |
| Net Profit Margin (TTM) | -14621.0% | · | · | · | |
| ROA (TTM) | -80.8%5Y avg ≈-47.0% | ≈-47.0% | -106.4% | Top tier | |
| ROE (TTM) | -99.9%5Y avg ≈-52.0% | ≈-52.0% | -135.0% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | LSTA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 3.75Y avg ≈8.5 | ≈8.5 | 4.3 | Low liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | LSTA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | LSTA | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$8.1K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
14.0%
Next Report
Nov 04, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Sept. 30, 2025 | $-0.49 | $-0.55 | 10.2% | |
| June 30, 2025 | $-0.54 | $-0.66 | 18.6% | |
| March 31, 2025 | $-0.55 | $-0.54 | -1.7% | |
| Dec. 31, 2024 | $-0.55 | $-0.78 | 29.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · | · | · | · | · | $35M | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | $31M | |
| R&D Expense | · | · | · | · | $18M | $9M | $11M | $8M | $16M | $17M | |
| SG&A Expense | $10M | $12M | $13M | $14M | $11M | $10M | $9M | $9M | $12M | $13M | |
| Operating Expenses | $18M | $23M | $26M | $58M | $29M | $19M | $20M | $17M | $28M | $30M | |
| Operating Income | $-18M | $-22M | $-26M | $-58M | $-29M | $-19M | $-20M | $-17M | $-28M | $-30M | |
| Interest Expense | · | · | · | · | · | · | $0 | $5.0K | $378.0K | $2M | |
| Other Non-op | $-145.0K | $-257.0K | $-186.0K | $-155.0K | $-75.0K | $0 | $740.0K | $824.0K | $273.0K | $23.9K | |
| Pretax Income | $-18M | $-21M | $-23M | $-57M | $-29M | $-19M | $-19M | $-16M | $-28M | $-31M | |
| Income Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-12M | $0 | |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| EPS (Basic) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | $-1.67 | $2.56 | $-4.99 | |
| EPS (Diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 | |
| Shares (Basic) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| Shares (Diluted) | 8,687,000 | 8,329,000 | 8,073,000 | 5,180,000 | 3,688,000 | 15,440,000 | · | 9,689,000 | 8,969,000 | 6,548,251 | |
| EBITDA | · | $-22M | $-26M | $-58M | · | $-19M | $-20M | $-17M | $-27M | $-30M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16M | $16M | $23M | $32M | $25M | $17M | $14M | $10M | $29M | $7M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $26M | $0 | |
| Receivables | $0 | $900.0K | $0 | · | · | · | · | · | $234.5K | $138.8K | |
| Prepaid Expense | $2M | $2M | $3M | $3M | $1M | $758.0K | $815.0K | $1M | $1M | $2M | |
| Current Assets | $18M | $35M | $54M | $72M | $96M | $35M | $26M | $44M | $61M | $25M | |
| PP&E (Net) | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K | $57.0K | $100.0K | $165.0K | $257.0K | $705.4K | |
| PP&E (Gross) | $494.0K | $661.0K | $661.0K | $713.0K | $430.0K | $370.0K | $349.0K | $349.0K | $1M | $2M | |
| Accum. Depreciation | $476.0K | $589.0K | $486.0K | $417.0K | $368.0K | $313.0K | $249.0K | $184.0K | $832.0K | $1M | |
| Goodwill | · | · | · | · | · | · | · | · | · | $7M | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $0 | · | · | · | · | $2M | |
| Other Non-current Assets | $23.0K | $160.0K | $332.0K | $528.0K | $764.0K | $614.0K | $1M | $309.0K | $2M | $2M | |
| Total Assets | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Accounts Payable | $1M | $1M | $2M | $3M | $2M | $1M | $1M | $762.0K | $1M | $2M | |
| Accrued Liabilities | $2M | $4M | $4M | $4M | $3M | $2M | $4M | $5M | $8M | $3M | |
| Short-term Debt | · | · | · | · | · | · | · | $0 | $159.0K | $563.8K | |
| Current Liabilities | $3M | $6M | $7M | $6M | $5M | $4M | $6M | $6M | $9M | $21M | |
| Capital Leases | $0 | $0 | $137.0K | $305.0K | $485.0K | $254.0K | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $1M | |
| Other Non-current Liabilities | $72.0K | $72.0K | $210.0K | $327.0K | $485.0K | $254.0K | $624.0K | $2M | $4M | $389.9K | |
| Total Liabilities | $3M | $6M | $7M | $7M | $5M | $4M | $7M | $7M | $13M | $30M | |
| Long-term Debt | · | · | · | · | · | · | · | · | $0 | $6M | |
| Total Debt | · | · | · | · | · | · | · | $0 | $159.2K | $6M | |
| Common Stock | $9.0K | $8.0K | $8.0K | $8.0K | $4.0K | $19.0K | $11.0K | $10.0K | $9.0K | $8.2K | |
| Paid-in Capital | $580M | $578M | $577M | $575M | $546M | $459M | $439M | $436M | $433M | $410M | |
| Retained Earnings | $-565M | $-548M | $-528M | $-507M | $-453M | $-426M | $-417M | $-398M | $-382M | $-405M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $707.6K | |
| AOCI | $-37.0K | $-81.0K | $-42.0K | $-29.0K | $-70.0K | $-13.0K | $2.0K | $-32.0K | $-28.0K | $0 | |
| Stockholders' Equity | $15M | $30M | $48M | $67M | $92M | $32M | $21M | $38M | $51M | $5M | |
| Liabilities + Equity | $18M | $35M | $55M | $73M | $97M | $36M | $27M | $45M | $63M | $54M | |
| Shares Outstanding | 8,833,875 | 8,410,000 | 8,151,000 | 7,867,000 | 3,986,000 | 1,292,000 | 10,517,609 | 9,865,735 | 9,483,911 | 8,205,790 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K | $100.0K | $100.0K | $200.0K | $400.0K | $500.0K | |
| Stock-based Comp | $1M | $2M | $2M | · | · | · | · | · | · | · | |
| Deferred Tax | $-962.0K | $-798.0K | $-2M | $-2M | $-2M | $-11M | $0 | $0 | $-576.0K | $0 | |
| Amort. of Intangibles | $65.0K | $71.0K | $71.0K | $21.0K | · | · | · | · | · | $570.0K | |
| Other Non-cash | · | · | $3M | $35M | · | $10M | $379.0K | $-4M | $-44M | $8M | |
| Operating Cash Flow | $-16M | $-19M | $-20M | $-21M | $-22M | $-9M | $-19M | $-20M | $-21M | $-24M | |
| CapEx | $28.0K | $0 | $0 | $285.0K | $60.0K | $20.0K | $0 | $134.0K | $135.0K | $1M | |
| Investing Cash Flow | $15M | $13M | $10M | $29M | $-55M | $-7M | $21M | $-5M | $41M | $-3M | |
| Net Debt Issued | · | · | · | · | · | · | · | $0 | $-6M | $-9M | |
| Stock Issued | $844.0K | $68.0K | $321.0K | $43.0K | $86M | $19M | · | · | · | · | |
| Net Stock Activity | · | $68.0K | $321.0K | $43.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $599.0K | $-206.0K | $385.0K | $-224.0K | $85M | $19M | $1M | $824.0K | $-932.0K | $21M | |
| Net Change in Cash | $-253.0K | $-6M | $-10M | $8M | $8M | $2M | $4M | $-24M | · | $-6M | |
| Taxes Paid | $6.0K | $6.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | $-20M | $-21M | · | $-9M | $-19M | $-20M | $-21M | $-27M | |
| Levered FCF | · | · | · | · | · | · | $-19M | $-20M | $-21M | $-28M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -2240.9% | · | · | · | · | · | · | · | -88.8% | |
| Net Margin | · | -1998.5% | · | · | · | · | · | · | · | -94.4% | |
| Pretax Margin | · | -2078.3% | · | · | · | · | · | · | · | -94.0% | |
| EBITDA Margin | · | -2240.9% | · | · | · | · | · | · | · | -83.7% | |
| ROA | · | -44.6% | -32.6% | -63.8% | · | -25.8% | -54.0% | -29.9% | 39.3% | -57.9% | |
| ROE | · | -51.4% | -36.3% | -68.3% | · | -30.6% | -66.1% | -36.6% | 83.0% | -232.9% | |
| ROIC | · | -72.9% | -48.0% | -82.7% | · | -25.2% | -96.5% | -45.0% | -31.8% | -276.4% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · | 10.1 | 4.3 | 7.8 | 6.6 | 1.3 | |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · | 4.7 | 2.3 | 1.8 | 5.9 | 0.9 | |
| Debt / Equity | · | · | · | · | · | · | · | 0.0 | 0.0 | 1.3 | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 0.0 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -3397.4 | -73.0 | -16.9 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · | · | · | · | · | 0.6 | |
| Receivables Turnover | · | 2.2 | · | · | · | · | · | · | · | 12.9 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $3.52 | $5.91 | $8.46 | · | $1.68 | $1.98 | $3.82 | $5.33 | $0.60 | |
| Revenue / Share | · | $0.12 | $0.00 | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-2.32 | $-2.48 | $-4.09 | · | · | · | $-2.06 | $-2.33 | · | |
| Cash / Share | · | $1.93 | $2.77 | $4.09 | · | $0.85 | $1.33 | $1.04 | $3.08 | $1.79 | |
| EPS (TTM) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 | · | · | $2.56 | $-4.99 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -83.0% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $170.0K | $1M | $0 | $0 | $33M | $33M | $33M | $33M | $33M | $35M | |
| Net Income TTM | $-17M | $-20M | $-21M | $-54M | $-27M | $-8M | $-19M | $-16M | $23M | $-33M | |
| Market Cap | · | $25M | $22M | $20M | · | $416M | $396M | $527M | $499M | $348M | |
| Enterprise Value | · | · | · | · | · | · | · | $517M | $444M | $340M | |
| P/E | -1.0 | -1.2 | -1.1 | -0.2 | -1.7 | -40.5 | · | · | 20.6 | -8.5 | |
| P/S | · | 25.1 | · | · | · | 12.6 | 12.0 | 15.9 | 15.1 | 9.9 | |
| P/B | · | 0.8 | 0.5 | 0.3 | · | 12.8 | 19.0 | 14.0 | 9.9 | 71.3 | |
| P / Tangible Book | 1.1 | 0.9 | 0.5 | 0.3 | 8.2 | 12.8 | · | · | · | · | |
| P / Cash Flow | · | -1.3 | -1.1 | -0.9 | · | -47.1 | -21.0 | -26.4 | -23.9 | -14.7 | |
| P / FCF | · | · | -1.1 | -0.9 | · | -47.0 | -21.0 | -26.2 | -23.8 | -13.1 | |
| EV / EBITDA | · | · | · | · | · | · | · | -30.8 | -16.3 | -11.5 | |
| EV / FCF | · | · | · | · | · | · | · | -25.7 | -21.2 | -12.8 | |
| EV / Revenue | · | · | · | · | · | · | · | 15.6 | 13.5 | 9.6 | |
| Earnings Yield | -102.7% | -80.5% | -94.5% | -413.8% | -59.1% | -2.5% | · | · | 4.9% | -11.8% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100.0K | $0 | $70.0K | $0 | $1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $3M | $4M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $3M | $4M | |
| Operating Expenses | $4M | $5M | $3M | $4M | $5M | $6M | $6M | $5M | $6M | $7M | $6M | $6M | $7M | $7M | $7M | $38M | |
| Operating Income | $-4M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-6M | $-7M | $-6M | $-6M | $-7M | $-7M | $-7M | $-38M | |
| Other Non-op | $984.0K | $-54.0K | $-15.0K | $-18.0K | $-7.0K | $-105.0K | $-11.0K | $-45.0K | $-14.0K | $-187.0K | $-12.0K | $-11.0K | $-150.0K | $-13.0K | $-7.0K | $0 | |
| Pretax Income | $-3M | $-5M | $-3M | $-4M | $-5M | $-6M | $-5M | $-5M | $-5M | $-6M | $-5M | $-5M | $-6M | $-6M | $-6M | $-37M | |
| Income Tax | $0 | $-387.0K | $0 | $0 | $0 | $-962.0K | $0 | $0 | $0 | $-798.0K | $0 | $0 | $-2M | $0 | $0 | $0 | |
| Net Income | $-3M | $-4M | $-3M | $-4M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-4M | $-6M | $-6M | $-37M | |
| EPS (Basic) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| EPS (Diluted) | $-0.32 | $-0.50 | $-0.33 | $-0.49 | $-0.54 | $-0.55 | $-0.55 | $-0.59 | $-0.61 | $-0.65 | $-0.66 | $-0.65 | $-0.50 | $-0.77 | $0.10 | $-7.88 | |
| Shares (Basic) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| Shares (Diluted) | 9,106,000 | 9,006,000 | · | 8,738,000 | 8,605,000 | 8,602,000 | · | 8,321,000 | 8,308,000 | 8,294,000 | · | 8,141,000 | 8,021,000 | 7,987,000 | · | 4,747,000 | |
| EBITDA | $-4M | $-5M | · | $-4M | $-5M | $-6M | · | $-5M | $-6M | $-7M | · | $-6M | $-7M | $-7M | · | $-38M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10M | $13M | $16M | $19M | $17M | $20M | $16M | $20M | $28M | $22M | $23M | $32M | $24M | $28M | $32M | $31M | |
| Receivables | · | · | $0 | · | · | · | $900.0K | · | · | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $570.0K | $960.0K | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $3M | $3M | $4M | $4M | $3M | $2M | |
| Current Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $42M | $48M | $54M | $57M | $61M | $65M | $72M | $77M | |
| PP&E (Net) | $14.0K | $16.0K | $18.0K | $22.0K | $48.0K | $74.0K | $72.0K | $96.0K | $119.0K | $146.0K | $175.0K | $204.0K | $233.0K | $262.0K | $296.0K | $299.0K | |
| PP&E (Gross) | $494.0K | $494.0K | $494.0K | $494.0K | $566.0K | $689.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $661.0K | $713.0K | · | |
| Accum. Depreciation | $480.0K | $478.0K | $476.0K | $472.0K | $518.0K | $615.0K | $589.0K | $565.0K | $542.0K | $515.0K | $486.0K | $457.0K | $428.0K | $399.0K | $417.0K | · | |
| Intangibles | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $400.0K | $400.0K | $400.0K | · | $352.0K | |
| Other Non-current Assets | $0 | $23.0K | $23.0K | $23.0K | $70.0K | $116.0K | $160.0K | $201.0K | $246.0K | $290.0K | $332.0K | $371.0K | $410.0K | $449.0K | $528.0K | $588.0K | |
| Total Assets | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Accounts Payable | $836.0K | $510.0K | $1M | $619.0K | $782.0K | $602.0K | $1M | $556.0K | $728.0K | $1M | $2M | $1M | $775.0K | $1M | $3M | $974.0K | |
| Accrued Liabilities | $2M | $3M | $2M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $4M | $5M | $7M | $5M | $4M | $5M | $6M | $6M | |
| Capital Leases | · | · | $0 | · | · | · | $0 | $0 | $47.0K | $92.0K | $137.0K | $181.0K | $223.0K | $265.0K | $305.0K | $345.0K | |
| Other Non-current Liabilities | $50.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $72.0K | $119.0K | $164.0K | $210.0K | $253.0K | $295.0K | $337.0K | $327.0K | $367.0K | |
| Total Liabilities | $3M | $3M | $3M | $5M | $4M | $4M | $6M | $5M | $5M | $5M | $7M | $5M | $5M | $6M | $7M | $7M | |
| Common Stock | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | $8.0K | |
| Paid-in Capital | $581M | $581M | $580M | $580M | $579M | $579M | $578M | $578M | $578M | $577M | $577M | $576M | $576M | $575M | $575M | $574M | |
| Retained Earnings | $-572M | $-569M | $-565M | $-562M | $-557M | $-553M | $-548M | $-543M | $-539M | $-533M | $-528M | $-523M | $-517M | $-513M | $-507M | $-501M | |
| Treasury Stock | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | $708.0K | |
| AOCI | $-17.0K | $-21.0K | $-37.0K | $-42.0K | $-50.0K | $-78.0K | $-81.0K | $-32.0K | $-77.0K | $-104.0K | $-42.0K | $-100.0K | $-50.0K | $-52.0K | $-29.0K | $-90.0K | |
| Stockholders' Equity | $8M | $11M | $15M | $17M | $21M | $25M | $30M | $34M | $38M | $43M | $48M | $53M | $58M | $61M | $67M | $72M | |
| Liabilities + Equity | $11M | $14M | $18M | $22M | $25M | $29M | $35M | $38M | $43M | $48M | $55M | $58M | $62M | $66M | $73M | $79M | |
| Shares Outstanding | 9,119,004 | 9,107,291 | 8,833,875 | 8,755,948 | 8,626,464 | 8,620,162 | 8,408,844 | 8,319,600 | 8,321,061 | 8,307,433 | 8,149,897 | 8,139,449 | 8,132,357 | 7,998,342 | 7,866,061 | 7,862,602 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.0K | $2.0K | $15.0K | $44.0K | $44.0K | $43.0K | $41.0K | $42.0K | $45.0K | $46.0K | $47.0K | $47.0K | $47.0K | $48.0K | · | $8.0K | |
| Stock-based Comp | $214.0K | $364.0K | · | · | $239.0K | $530.0K | · | · | · | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $0 | $0 | $12.0K | $18.0K | $18.0K | $17.0K | $18.0K | $18.0K | $18.0K | $17.0K | $17.0K | $18.0K | $18.0K | $18.0K | $18.0K | · | |
| Operating Cash Flow | $-3M | $-3M | $-3M | $-3M | $-4M | $-5M | $-5M | $-3M | $-5M | $-7M | $-4M | $-4M | $-4M | $-8M | $-6M | $-4M | |
| CapEx | $0 | $0 | $0 | $0 | $0 | $28.0K | $0 | $0 | $0 | $0 | · | $0 | · | · | $26.0K | $24.0K | |
| Investing Cash Flow | $0 | $0 | $0 | $5M | $505.0K | $9M | $1M | $-6M | $12M | $6M | $-6M | $12M | $-725.0K | $4M | $7M | $2M | |
| Stock Issued | $29.0K | $0 | $205.0K | $353.0K | $74.0K | $212.0K | $36.0K | $0 | $32.0K | $0 | $24.0K | $0 | · | · | $14.0K | $0 | |
| Net Stock Activity | · | $0 | · | · | · | $212.0K | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $29.0K | $181.0K | $205.0K | $353.0K | $64.0K | $-23.0K | $-96.0K | $0 | $32.0K | $-142.0K | $24.0K | $-6.0K | $452.0K | $-85.0K | $14.0K | $-99.0K | |
| Net Change in Cash | $-3M | $-3M | $-3M | $2M | $-3M | $4M | $-3M | $-9M | $6M | $-788.0K | $-10M | $9M | $-4M | $-4M | $676.0K | $-2M | |
| Free Cash Flow | · | $-3M | · | · | · | $-5M | · | · | · | · | · | · | · | · | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Pretax Margin | · | · | · | · | -6655.7% | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -6954.3% | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -16.2% | -20.9% | · | -14.2% | -13.8% | -12.2% | · | -10.2% | -9.6% | -9.4% | · | -7.7% | -5.4% | -7.8% | · | -41.3% | |
| ROE | -20.0% | -24.8% | · | -16.6% | -15.7% | -13.8% | · | -11.4% | -10.5% | -10.4% | · | -8.4% | -5.7% | -8.3% | · | -43.8% | |
| ROIC | -48.4% | -41.6% | · | -25.4% | -23.2% | -19.2% | · | -15.8% | -14.4% | -13.4% | · | -11.3% | -7.5% | -11.2% | · | -52.4% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 4.2 | · | 4.7 | 5.8 | 7.5 | · | 8.0 | 9.4 | 8.9 | · | 11.2 | 14.1 | 12.4 | · | 12.1 | |
| Quick Ratio | 3.5 | 3.9 | · | 4.2 | 3.9 | 5.3 | · | 4.2 | 6.3 | 4.1 | · | 6.3 | 5.4 | 5.3 | · | 4.9 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.90 | $1.20 | · | $1.98 | $2.44 | $2.94 | · | $4.05 | $4.60 | $5.18 | · | $6.51 | $7.13 | $7.62 | · | $9.16 | |
| Revenue / Share | $0.00 | $0.00 | · | $0.00 | $0.01 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.34 | · | · | · | $-0.63 | · | · | · | $-0.85 | · | · | · | $-1.03 | · | · | |
| Cash / Share | $1.15 | $1.43 | · | $2.17 | $1.95 | $2.35 | · | $2.34 | $3.40 | $2.62 | · | $3.98 | $2.91 | $3.52 | · | $4.00 | |
| EPS (TTM) | $-1.64 | $-1.86 | · | $-2.13 | $-2.23 | $-2.30 | · | $-2.51 | $-2.57 | $-2.46 | · | $-1.82 | $-9.05 | $-10.19 | · | $-15.99 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $100.0K | $170.0K | · | $1M | $1M | $1M | · | $0 | $0 | $0 | · | $0 | $0 | · | · | · | |
| Net Income TTM | $-15M | $-16M | · | $-18M | $-19M | $-19M | · | $-21M | $-21M | $-20M | · | $-21M | $-54M | $-56M | · | $-55M | |
| Market Cap | $31M | $46M | · | $23M | $25M | $20M | · | $25M | $29M | $26M | · | $17M | $30M | $26M | · | $36M | |
| P/E | -2.1 | -2.7 | · | -1.2 | -1.3 | -1.0 | · | -1.2 | -1.4 | -1.3 | · | -1.2 | -0.4 | -0.3 | · | -0.3 | |
| P/S | 310.0 | 268.4 | · | 21.4 | 23.4 | 20.3 | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.8 | 4.2 | · | 1.3 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Tangible Book | 4.0 | 4.3 | · | 1.4 | 1.2 | 0.8 | · | 0.7 | 0.8 | 0.6 | · | 0.3 | 0.5 | 0.4 | · | 0.5 | |
| P / Cash Flow | · | -14.8 | · | · | · | -3.8 | · | · | · | -3.7 | · | · | · | -3.2 | · | · | |
| Earnings Yield | -48.2% | -37.1% | · | -81.3% | -76.9% | -97.9% | · | -83.7% | -74.1% | -78.8% | · | -85.0% | -244.6% | -313.5% | · | -345.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $170.0K | $1M | $0 | $0 | · |
| Operating Margin % | · | -2240.9% | · | · | · |
| Net Income | $-17M | $-20M | $-21M | $-54M | $-27M |
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | · | 6.2 | 8.2 | 11.3 | · |
| Quick Ratio | · | 3.0 | 3.4 | 5.0 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | $-20M | $-21M | · |
Institutional owners (13F) 34 filers · $4.1M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
34
Value held
$4.1M
New positions
3
Exited positions
5
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 3 (-11 vs prior Q) | 5 (+1 vs prior Q) | 9 (+4 vs prior Q) | 5 (+2 vs prior Q) | +32K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $948,046 | 278,837 | 23.31% | Shares |
| VANGUARD GROUP INC | $503,891 | 270,909 | 12.39% | Shares |
| Yakira Capital Management, Inc. | $471,107 | 138,561 | 11.58% | Shares |
| CSS LLC/IL | $375,435 | 110,422 | 9.23% | Shares |
| DELTEC ASSET MANAGEMENT LLC | $282,870 | 83,197 | 6.96% | Shares |
| Rangeley Capital, LLC | $275,400 | 81,000 | 6.77% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $246,999 | 72,632 | 6.07% | Shares |
| BlackRock, Inc. | $186,514 | 54,857 | 4.59% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $166,478 | 48,964 | 4.09% | Shares |
| GTS SECURITIES LLC | $102,680 | 30,200 | 2.52% | Shares |
| STATE STREET CORP | $86,183 | 25,348 | 2.12% | Shares |
| JANE STREET GROUP, LLC | $63,720 | 18,741 | 1.57% | Shares |
| CITADEL ADVISORS LLC | $52,839 | 15,541 | 1.30% | Shares |
| NORTHERN TRUST CORP | $52,816 | 15,534 | 1.30% | Shares |
| JBF Capital, Inc. | $48,780 | 14,347 | 1.20% | Shares |
| Cerity Partners LLC | $41,422 | 12,183 | 1.02% | Shares |
| BANK OF AMERICA CORP /DE/ | $35,200 | 10,353 | 0.87% | Shares |
| HighTower Advisors, LLC | $34,143 | 10,042 | 0.84% | Shares |
| SOL Capital Management CO | $29,342 | 12,175 | 0.72% | Shares |
| COOK WEALTH MANAGEMENT GROUP LLC | $29,342 | 12,175 | 0.72% | Shares |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $16,800 | 5,000 | 0.41% | Shares |
| Founders Capital Management | $5,668 | 1,667 | 0.14% | Shares |
| Vanguard Global Advisers, LLC | $3,512 | 1,033 | 0.09% | Shares |
| Connective Capital Management, LLC | $3,454 | 1,016 | 0.08% | Shares |
| Tower Research Capital LLC (TRC) | $2,468 | 726 | 0.06% | Shares |
| OSAIC HOLDINGS, INC. | $680 | 200 | 0.02% | Shares |
| Caitong International Asset Management Co., Ltd | $306 | 90 | 0.01% | Shares |
| MORGAN STANLEY | $255 | 75 | 0.01% | Shares |
| BARCLAYS PLC | $238 | 70 | 0.01% | Shares |
| Virtu Financial LLC | $200 | 58,782 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $24 | 7 | 0.00% | Shares |
| Cheviot Value Management, LLC | $10 | 3 | 0.00% | Shares |
| Fortitude Family Office, LLC | $3 | 1 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 52 | 0.00% | Shares |
Activists & 5%+ owners 20 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RimAsia Capital Partners, L.P., RimAsia Capital Partners GP, L.P., RimAsia Capital Partners GP, Ltd., Eric H.C. Wei ×8 filings | May 20, 2010 | · | Initial filing | Passive investment | SEC |
| Robin L. Smith | Sept. 10, 2009 | · | Initial filing | Passive investment | SEC |
| Catherine M. Vaczy | Sept. 10, 2009 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Nov. 16, 2007 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Oct. 30, 2007 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Feb. 20, 2007 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Jan. 5, 2007 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 15, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 29, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | June 29, 2006 | · | Initial filing | Passive investment | SEC |
| Mark Weinreb | June 29, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | June 28, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Dec. 8, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Aug. 31, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Aug. 4, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Aug. 2, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Aug. 2, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | Aug. 1, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | April 29, 2005 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person | Sept. 23, 2004 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 51 insiders · 29 officers · 17 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Joseph Talamo | SVP and CFO | Jan. 13, 2020 A | 59,644 | 0 | 0 | $0 |
| Robert S Vaters | President & CFO | Aug. 12, 2015 P | 228,750 | 0 | 0 | $0 |
| Robert Dickey IV | Chief Financial Officer | Dec. 31, 2014 A | 12,066 | 0 | 0 | $0 |
| Larry Alan May | Chief Financial Officer | Jan. 2, 2013 A | 64,618 | 0 | 0 | $0 |
| David W. Slack | President & CBO | Jan. 9, 2023 A | 20,642 | 0 | 0 | $0 |
| Hans Keirstead | President of the Issuer's NeoStem Oncology, LLC subsidiary. | May 9, 2014 A | · | 0 | 0 | $0 |
| Ian Zhang | President and Managing Director, NeoStem (China), Inc. | April 4, 2011 A | 10,000 | 0 | 0 | $0 |
| Mark Weinreb | President | May 21, 2009 A | 66,923 | 0 | 0 | $0 |
| Robert Joseph Aholt JR | Chief Operating Officer | Oct. 3, 2005 A | 4,369,317 | 0 | 0 | $0 |
| Tariq Imam | SVP, Bus Dev, General Counsel | Jan. 9, 2026 A | 36,078 | 0 | 0 | $0 |
| James Nisco | SVP, Fin/Treas, Chief Actg Off | Jan. 9, 2026 A | 32,311 | 0 | 0 | $0 |
| Kristen K Buck | EVP, R&D and CMO | Jan. 9, 2026 A | 93,462 | 0 | 0 | $0 |
| Todd C Girolamo | CLO, SVP of Corp Dev | Jan. 14, 2022 F | 160,827 | 0 | 0 | $0 |
| Douglas W Losordo | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | Jan. 13, 2020 A | 130,406 | 0 | 0 | $0 |
| Robin L Smith | Executive Chair of the Board | June 2, 2015 A | 347,285 | 0 | 0 | $0 |
| Catherine M Vaczy | General Counsel | April 13, 2015 A | 71,234 | 0 | 0 | $0 |
| Stephen W Potter | Executive Vice President | Dec. 31, 2014 A | 14,016 | 0 | 0 | $0 |
| Robert Dillman | Vice President, Oncology of the Issuer. The Reporting Person also serves as Chief Medical Officer of the Issuer's NeoStem Oncolo | May 9, 2014 A | · | 0 | 0 | $0 |
| Martin E Schmieg | Vice President - Corporate Dev | June 25, 2012 A | · | 0 | 0 | $0 |
| Jonathan Sackner-Bernstein | VP Clinical Dev & Reg Affairs | April 2, 2012 A | · | 0 | 0 | $0 |
| Jason Kolbert | VP of Strategic Business Development | Jan. 4, 2012 A | 8,000 | 0 | 0 | $0 |
| Mingsheng Shi | Chairman of the Board of Directors of Suzhou Erye Pharmaceutical Company Ltd., an entity 51%-owned by the Company. | Jan. 4, 2012 A | 3,650,770 | 0 | 0 | $0 |
| Alan G Harris | Vice President of Regenerative Medicine, Drug Development and Regulatory Affairs | April 4, 2011 A | · | 0 | 0 | $0 |
| Anthony Salerno | Vice President, Operations and Academic Affairs Exhibit List Exhibit 24 - Power of Attorney | June 9, 2010 A | · | 0 | 0 | $0 |
| Jian M Zhang | Vice President, Pharmaceutical Operations, and General Manager of Suzhou Erye Pharmaceuticals Company Ltd., a 51% owned subsidi | June 9, 2010 A | 3,650,770 | 0 | 0 | $0 |
| Christopher C Duignan | Vice President, Finance | Nov. 30, 2009 A | · | 0 | 0 | $0 |
| Lepore Teresa Linn Samuels | VP of Sales and Marketing | Oct. 29, 2009 A | · | 0 | 0 | $0 |
| Renee Cohen | VP of Oper. & Corp. Strategy | Feb. 27, 2008 A | 31,000 | 0 | 0 | $0 |
| Wayne A Marasco | Senior Scientific Advisor | June 2, 2006 A | 1,436,713 | 0 | 0 | $0 |
| Cynthia Schwalm | Director | Jan. 9, 2026 A | 95,446 | 0 | 0 | $0 |
| Steven M Klosk | Director | Jan. 9, 2026 A | 95,815 | 0 | 0 | $0 |
| Anne Clem Whitaker | Director | Jan. 10, 2022 A | 182,635 | 0 | 0 | $0 |
| Michael H. Davidson | Director | Jan. 10, 2022 A | 209,753 | 0 | 0 | $0 |
| MYERS STEVEN S | Director | Jan. 10, 2022 A | 212,269 | 0 | 0 | $0 |
| Eric Wei | Director | Feb. 7, 2017 S | 172,223 | 0 | 0 | $0 |
| Richard J Berman | Director | Jan. 9, 2017 A | 7,177 | 0 | 0 | $0 |
| Andrew L Pecora | Director | June 22, 2016 A | 393,784 | 0 | 0 | $0 |
| Drew Bernstein | Director | June 2, 2015 A | 10,000 | 0 | 0 | $0 |
| Martyn D Greenacre | Director | June 2, 2015 A | 88,531 | 0 | 0 | $0 |
| Edward Geehr | Director | June 29, 2012 A | · | 0 | 0 | $0 |
| Joseph Zuckerman | Director | May 21, 2009 A | 41,260 | 0 | 0 | $0 |
| RimAsia Capital Partners Manager, Ltd. | 10% owner | Sept. 17, 2012 S | 105,306 | 0 | 0 | $0 |
| Fullbright Finance Ltd | 10% owner | Dec. 28, 2009 P | 3,250,770 | 0 | 0 | $0 |
| Gregory B Brown | · | Jan. 9, 2026 A | 95,659 | 0 | 0 | $0 |
| David J Mazzo | · | Jan. 9, 2026 A | 311,890 | 0 | 0 | $0 |
| Mohammad Azab | · | Jan. 9, 2026 A | 104,925 | 0 | 0 | $0 |
| Heidi Henson | · | Jan. 9, 2026 A | 85,725 | 0 | 0 | $0 |
| Erkki Ruoslahti | · | Jan. 9, 2023 A | 20,000 | 0 | 0 | $0 |
| Peter G Traber | · | Jan. 10, 2022 A | 149,190 | 0 | 0 | $0 |
| Robert A Preti | · | May 18, 2017 F | 33,786 | 0 | 0 | $0 |
| Aholt Jr Family Trust | · | June 5, 2006 S | 12,352,227 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
LSTA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 9 analysts
BUY
Median target
$4.00
+172.1%
2 22.2%
Strong Buy
4 44.4%
Buy
3 33.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
1 analysts · 2026-07-19Mean target $4.00 +172.1%
Low$4.00
Mean$4.00
High$4.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026